Related Experiment Videos
Prostaglandin inhibitors as tocolytic agents
1Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA. vermills@musc.edu
Seminars in Perinatology
|September 20, 2001
Summary
Indomethacin is a potent tocolytic for acute treatment, but requires careful use due to potential fetal and neonatal risks. Newer cyclooxygenase-2 (COX-2) inhibitors offer potential benefits with fewer side effects.
Area of Science:
- Pharmacology
- Obstetrics
- Neonatal Medicine
Background:
- Indomethacin, a prostaglandin synthetase inhibitor, was a popular tocolytic agent.
- Concerns regarding fetal and neonatal complications tempered its use.
- Renewed interest in indomethacin for acute tocolysis exists due to better recognition of safety limitations.
Purpose of the Study:
- Review the pharmacology and efficacy of indomethacin and cyclooxygenase-2 (COX-2) inhibitors.
- Discuss potential adverse fetal and neonatal effects.
- Provide guidelines for safe and effective tocolysis with indomethacin.
Main Methods:
- Literature review of indomethacin and COX-2 inhibitors.
- Analysis of pharmacological properties and clinical efficacy.
- Evaluation of fetal and neonatal safety data.
Main Results:
- Indomethacin demonstrates potent tocolytic effects.
- COX-2 inhibitors show promise for tocolysis with potentially fewer side effects.
- Adverse fetal and neonatal effects are associated with indomethacin use.
Conclusions:
- Indomethacin remains a viable option for acute tocolysis when safety limitations are recognized.
- COX-2 inhibitors represent a promising alternative for tocolysis.
- Clinical guidelines are essential for optimizing indomethacin use and minimizing risks.